Comparing Endoscopic Biopsy to Surgery Samples for Molecular Testing in Gastric Cancer Evaluating Reliability of Biopsy for Diagnosing Gastric Adenocarcinoma

What this Trial Is About

Researchers are evaluating whether testing for various molecular and histological features of gastric cancer, such as histological type, grade, LAUREN type, HER-2 expression, MSIdMMR status, and EBV status, is as reliable on preoperative endoscopic biopsy samples as on surgical resection specimens. This is important because some gastric cancers treated before surgery may show no remaining tumor, making surgical specimens unavailable for testing. Using biopsy specimens could allow earlier genetic information to guide treatment decisions. The study compares the testing results from two sources endoscopic biopsy specimens obtained before surgery using a gastroscope, and surgical resection specimens collected during radical gastrectomy. Both sets of samples are analyzed for the listed molecular and histological markers. The study is observational and does not involve experimental treatments but monitors and compares diagnostic accuracy and testing completeness from these two specimen types. Participants will undergo endoscopy to collect biopsy samples and then have surgery to remove the tumor for further testing. Researchers will assess the diagnostic accuracy over two years, the proportion of incomplete molecular pathology results, and procedure duration. The study involves informed consent, pathology assessments, and follows participants through the diagnostic process to understand if biopsy samples can reliably replace surgical specimens for molecular diagnosis in gastric cancer.

Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer